TITLE

Gene therapy: two steps forward, one step back

AUTHOR(S)
Johnston, Josephine; Baylis, Francoise
PUB. DATE
June 2004
SOURCE
CMAJ: Canadian Medical Association Journal;6/8/2004, Vol. 170 Issue 12, p1785
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the gene therapy trial involving children with X-linked sever combined immunodeficiency disease (X-SCID) which began in 1999 in Paris, France. Setback to the Paris trial; Reaction of the international community in the first case of leukemia in the Paris trial; Harm-benefit analysis of gene therapy trial.
ACCESSION #
13258283

 

Related Articles

  • Gene therapy: Shining hopes dented — but not dashed. Check, Erika // Nature;12/19/2002-12/26/2002, Vol. 420 Issue 6917, p735 

    Reports on the impact of a gene therapy trial wherein a patient with severe combined immunodeficiency disease had developed leukemia. Cause of the patient's leukemia; Trials put on hold following the setback.

  • Strategy Escalation: An emerging paradigm for safe clinical development of T cell gene therapies. Junghans, Richard Paul // Journal of Translational Medicine;2010, Vol. 8, p55 

    Gene therapy techniques are being applied to modify T cells with chimeric antigen receptors (CARs) for therapeutic ends. The versatility of this platform has spawned multiple options for their application with new permutations in strategies continually being invented, a testimony to the creative...

  • Gene therapists hopeful as trials resume with childhood disease. Check, Erika // Nature;6/10/2004, Vol. 429 Issue 6992, p587 

    Reports that a French gene-therapy trial that cured nine children of severe disease, but gave two of them cancer, is set to restart after a 22-month suspension. Background of the clinical trial; Risk that some children will develop cancer during the trials; Efforts to balance the risk of cancer...

  • Wilson faces life ban. Birmingham, Karen // Nature Medicine;Jan2001, Vol. 7 Issue 1, p6 

    Reports that the U.S. Food and Drug Administration has started proceedings against head of the Philadelphia, Pennsylvania-based Institute for Human Gene Therapy's James Wilson which may lead to his being banned for life from clinical experimentation. Allegations against Wilson for failing to...

  • Human Gene Therapy in Coming Months? Marwick, Charles // JAMA: Journal of the American Medical Association;7/18/90, Vol. 264 Issue 3, p314 

    Reports on a plan regarding the clinical trial of human gene therapy developed by the Human Gene Therapy Subcommittee. Approvals needed by the planned study; Requests from subcommittee members; Study that the group will use for the clinical trial.

  • Gene therapy researchers bemoan dual regulations. Ready, Tinker // Nature Medicine;Jul2001, Vol. 7 Issue 7, p756 

    Reports that gene therapy researchers in the U.S. expressed their unhappiness regarding the rules set for gene therapy clinical trials. Agencies to whom researchers have to report while conducting clinical trials; Reason behind the unhappiness among the researchers; Differences among agencies...

  • Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Norris, J S; Bielawska, A; Day, T; El-Zawahri, A; ElOjeimy, S; Hannun, Y; Holman, D; Hyer, M; Landon, C; Lowe, S; Dong, J Y; McKillop, J; Norris, K; Obeid, L; Rubinchik, S; Tavassoli, M; Tomlinson, S; Voelkel-Johnson, C; Liu, X // Cancer Gene Therapy;Dec2006, Vol. 13 Issue 12, p1045 

    As of January 2005, there were 1020 gene therapy clinical trials ongoing worldwide with 675 or 66.2% devoted to cancer gene therapy. The majority are occurring in the US and Europe (http://www.wiley.co.uk/genetherapy/clinical/). At the present time, to our knowledge there are no trials that...

  • New Approach for Easing Angina. March, Keith // Medical Update;2003, Vol. 29 Issue 6, p6 

    Presents information on the Angiogenic Gene Therapy in Patients with Stable Angina (AGENT) trial conducted by researchers at Indiana University School of Medicine and the Indiana Center for Vascular Biology and Medicine in December 2003. Patients who are eligible for the AGENT trial; Delivery...

  • Why Were NIH Adverse Event Reporting Guidelines Misunderstood? Finn, Robert // JNCI: Journal of the National Cancer Institute;05/17/2000, Vol. 92 Issue 10, p784 

    Looks at the widespread confusion among investigators regarding adverse event reporting in the United States (US). Claims of unreported serious adverse events (SAE) in some clinical trials; Actions taken by the US National Institutes of Health and the US Food and Drug Administration to simplify...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics